Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st.

Artelo Biosciences Price Performance

ARTL opened at $1.16 on Monday. Artelo Biosciences has a 12-month low of $1.00 and a 12-month high of $1.75. The stock has a market capitalization of $3.74 million, a PE ratio of -0.40 and a beta of 1.29. The firm’s fifty day moving average price is $1.14 and its 200 day moving average price is $1.24.

Artelo Biosciences (NASDAQ:ARTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. On average, equities research analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.